Core Insights - Chengdu XianDao Pharmaceutical Development Co., Ltd. aims to establish itself as a leading innovative biopharmaceutical company, focusing on new drug discovery and optimization, while integrating sustainable development practices into its operations [1][2][3] Company Overview - Chengdu XianDao is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK, and Houston, USA, specializing in small molecule and nucleic acid drug discovery [2][3] - The company has developed a DNA-encoded compound library (DEL) technology platform, which is recognized as a global leader in the field [3][4] Sustainable Development Practices - The company has published its first sustainability report, outlining its commitment to environmental, social, and governance (ESG) principles, and aims to respond to stakeholder concerns [1][2] - Chengdu XianDao integrates sustainable development concepts into its operations, focusing on low-carbon transformation, talent development, and community welfare [2][3] Governance Structure - The company has established a robust governance framework to ensure transparency and compliance, including a board of directors with diverse expertise in the biopharmaceutical industry [5][6] - Chengdu XianDao has implemented various governance policies and procedures to enhance decision-making processes and risk management [5][6] Innovation and R&D - The company emphasizes innovation as a key driver for sustainable development, investing in technology upgrades and automation to enhance drug discovery capabilities [2][3] - Chengdu XianDao has a comprehensive training system to support employee development and foster a culture of innovation [2][5] Environmental Management - The company adheres to eco-friendly practices and has received ISO 9001 certification for its quality management system, demonstrating its commitment to environmental compliance [2][3] - Chengdu XianDao actively works to reduce its environmental impact through various measures, including resource efficiency and waste management [2][3] Stakeholder Engagement - The company has established a framework for ongoing communication with stakeholders, ensuring their concerns and expectations are addressed [7][8] - Chengdu XianDao identifies key issues through stakeholder feedback and integrates these insights into its strategic planning [7][8]

Core Viewpoint - Chengdu Xian Dao announced the termination of its major asset restructuring deal with Nanjing Haina Pharmaceutical Technology Co., Ltd. after failing to reach consensus on key terms [1][3]. Group 1: Transaction Details - Chengdu Xian Dao intended to acquire approximately 65% of Haina Pharmaceutical through a cash equity transfer [3]. - Despite signing a letter of intent and conducting due diligence, the parties could not agree on core terms such as price, management control, and future strategic direction [3]. - The termination of this deal signifies a setback for Haina Pharmaceutical's plans for an IPO, which had been under review since June 30, 2023, and was ultimately withdrawn on June 24, 2024 [4]. Group 2: Company Performance - Chengdu Xian Dao's financial performance has shown a decline since its IPO, with net profits reported as approximately 64.02 million, 63.38 million, 25.27 million, 40.72 million, and 51.36 million from 2020 to 2024 [5]. - The company's stock has experienced a decline, with a current price of 16.57 yuan per share compared to the initial offering price of 20.52 yuan [5]. - The controlling shareholder, JIN LI, plans to increase his stake in the company by investing between 25 million and 50 million yuan within the next 12 months, indicating confidence in the company's long-term value [5].

Group 1 - Longqi Technology has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [1] - Chengdu XianDao has terminated the acquisition of approximately 65% equity in Nanjing Haina Pharmaceutical Technology Co., Ltd. due to failure to reach consensus on core terms [4] - Unigroup Guowei repurchased 775,500 shares for a total amount of 49.6173 million yuan on June 27 [5] Group 2 - Qinhuangdao State-owned Assets Supervision and Administration Commission plans to reduce its stake in Qin Port Co., Ltd. by up to 2% [2] - Magu Technology's shareholder Baolifeng intends to reduce its stake by up to 3% [3] - New Dairy's controlling shareholder plans to reduce its stake by up to 3% due to funding needs [6] Group 3 - Mindray Medical's shareholder EverUnion (H.K.) Limited plans to reduce its stake by up to 500,000 shares, representing approximately 0.41% of the total share capital [7] - Degute plans to acquire control of Haowei Technology, with trading suspended from June 30 [8]

经过接近三个月的筹划，成都先导(688222)在6月29日宣布宣布终止重大资产重组计划，各方未能就核 心条款达成一致。 成都先导方面表示，自与交易对方确立交易意向以来，公司积极组织交易各方推进本次交易。鉴于交易 各方未能就交易方案、交易价格、交易对方范围、业绩承诺等核心条款达成一致，为切实维护公司及全 体股东利益，经公司充分审慎研究并与交易对方友好协商，交易各方一致同意终止本次交易事项。 根据前期披露的方案，成都先导原计划收购南京海纳医药科技股份有限公司(简称"海纳医药")约65%的 股权。经初步测算，交易预计构成重大资产重组情形。 围绕这笔收购，各方在3月31日签署《股权收购意向书》，随后成都先导聘请中介机构对海纳医药展开 尽调，组织各相关方就本次交易方案进行论证商讨，与交易各方就本次交易的交易方案、交易价格、交 易对方范围、业绩承诺等事项进行多轮谈判沟通。 "此次收购是通过资源整合、市场拓展和风险对冲，实现公司战略短期与长期的更平衡发展。"成都先导 方面曾这样概括收购海纳医药对公司的价值。 在本次重组终止后，双方后续或许还会有业务层面的合作落地。成都先导方面透露，本次合作虽未达成 最终目标，但是海纳医药对 ...

CONTENTS 目录 关于本报告 董事长兼首席执行官致辞 关于成都先导 附录 附录 1：ESG 绩效 附录 2：《上海证券交易 所上市公司自律监管指引 第 14 号——可持续发展 报告（试行）》索引 附录 3：《PSCI 负责任供 应链管理原则》索引 62 | 01 | | | | | --- | --- | --- | --- | | 02 | 可持续的 | | | | 03 | 公司治理 | | 负责任的 | | | 公司治理 | 08 | 价值链 | | | ESG 管治 | 10 | | | | 商业道德 | 14 | | | | 内控与风险管理 | 16 | | | 56 | | | | | 61 | | | | | 负责任的 | | | --- | --- | | 价值链 | | | 负责任供应链 | 19 | | 创新驱动 | 24 | | 产品质量与客户服务 | 29 | | 数据安全与隐私保护 | 32 | | 和谐共进的 | | | --- | --- | | 内外部生态 | 生态友好的 | | 员工权益 | 35 环境管理 | | 员工关爱与福利 | 38 | | 多元平等与包容 | ...

成都先导药物开发股份有限公司 关于终止重大资产重组的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都先导药物开发股份有限公司（以下简称"公司"）于 2025 年 4 月 1 日披 露了《成都先导药物开发股份有限公司关于筹划重大资产重组暨签署<股权收购 意向书>的提示性公告》（公告编号：2025-004），拟以现金方式受让股权的方式 合计取得南京海纳医药科技股份有限公司（以下简称"标的公司"）约 65%的股 权（以下简称"本次交易"）。《股权收购意向书》签署后，公司积极组织交易各 方推进本次交易，聘请了专业的中介机构对标的公司展开尽调，在此基础上，交 易各方对本次交易方案进行多次论证和协商，但未能就本次交易事项的核心条款 达成一致意见。为切实维护公司及全体股东利益，经公司充分审慎研究并与交易 对方友好协商，交易各方一致同意终止本次交易事项，本次重大资产重组事项终 止。现就有关情况公告如下： 一、本次筹划重大资产重组的基本情况 证券代码：688222 证券简称：成都先导 公告编号：2025-027 三、终止筹划 ...

Group 1 - The conference held in Chengdu focused on the role of mergers and acquisitions (M&A) in promoting industrial upgrades, with participation from representatives of listed companies, financial institutions, and various industry leaders [1] - Since the beginning of 2024, Sichuan listed companies have initiated or implemented 74 M&A transactions, totaling over 29 billion yuan, with 5 transactions starting after the new restructuring regulations were released on May 16, further stimulating market activity [3] - The new M&A regulations support cross-industry mergers, allow acquisitions of unprofitable assets, and aim to enhance regulatory tolerance, transaction efficiency, and intermediary service levels, facilitating companies to pursue growth through strategic acquisitions [3] Group 2 - Chengdu is actively promoting industrialization and the development of new productive forces, viewing M&A as a means for companies to quickly acquire core technologies, expand market reach, and optimize talent structures, while also serving as a driver for resource integration and modern industrial system construction [3] - The Chengdu Economic and Information Bureau is committed to assisting enterprises in utilizing M&A strategies and has initiated the establishment of a 2 billion yuan M&A fund focused on the health industry, marking the first such fund in Central and Western China [4] - In September 2024, Chengdu's Jiaozi Financial Holdings Group, in collaboration with Guojin Securities and other stakeholders, registered a 400 million yuan M&A fund, which is the first locally led fund focusing on M&A in strategic emerging industries such as advanced manufacturing and information technology [5]

成都先导药物开发股份有限公司 简式权益变动报告书 上市公司名称：成都先导药物开发股份有限公司 股票上市地点：上海证券交易所 股票简称：成都先导 股票代码：688222 信息披露义务人：安吉东方佳钰企业管理合伙企业（有限合伙） 注册地址：浙江省湖州市安吉县灵峰街道浮玉南路 61 号（金融大厦） 通讯地址：浙江省湖州市安吉县天目中路 531 号 权益变动性质：股份减少（持股比例下降至 5%） 签署日期：2025 年 6 月 23 日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》 《中华人民共和国证券法》、 《上市公司收购管理办法》 、《公开发行证 券的公司信息披露内容与格式准则第 15 号——权益变动报告书》及 其他相关法律、法规和部门规章的有关规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其 履行亦不违反信息披露义务人公司章程或内部规则中的任何条款，或 与之相冲突。 三、依据《中华人民共和国证券法》、 《上市公司收购管理办法》 和《公开发行证券的公司信息披露内容与格式准则第 15 号——权益 变动报告书》的规定，本报告书已全面披露信息披露义务人在成都先 导药物 ...

证券代码：688222 证券简称：成都先导 公告编号：2025-026 成都先导药物开发股份有限公司 关于持股 5%以上股东权益变动 暨减持股份结果的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： （公告编号：2025-003），东方佳钰拟通过集中竞价交易或大宗交 易的方式减持其所持有的公司股份不超过 4,817,500 股，拟减持股份占 公司总股本的比例约为 1.20%，其中： （1）拟通过集中竞价交易的方式 减持的，自减持计划发布之日起 15 个交易日之后的 3 个月内（2025 年 3 月 24 日至 2025 年 6 月 23 日）实施，且任意连续 90 个自然日内 减持的股份总数不超过公司股份总数的 1%； （2）拟通过大宗交易的方 式减持的，自减持计划发布之日起 15 个交易日后的 3 个月内（2025 年 3 月 24 日至 2025 年 6 月 23 日）实施，且任意连续 90 个自然日内 减持的股份总数不超过公司股份总数的 2%。 公司于近日收到东方佳钰出具的《简式 ...

成都先导药物开发股份有限公司 简式权益变动报告书 上市公司名称：成都先导药物开发股份有限公司 股票上市地点：上海证券交易所 股票简称：成都先导 股票代码：688222 信息披露义务人：安吉东方佳钰企业管理合伙企业（有限合伙） 注册地址：浙江省湖州市安吉县灵峰街道浮玉南路 61 号（金融大厦） 1 幢 2304 号 29 室 通讯地址：浙江省湖州市安吉县天目中路 531 号 权益变动性质：股份减少（持股比例下降至 5%） 签署日期：2025 年 6 月 23 日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》、 《中华人民共和国证券法》、《上市公司收购管理办法》、《公开发行证 券的公司信息披露内容与格式准则第 15 号——权益变动报告书》及 其他相关法律、法规和部门规章的有关规定编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其 履行亦不违反信息披露义务人公司章程或内部规则中的任何条款，或 与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》 和《公开发行证券的公司信息披露内容与格式准则第 15 号——权益 变动报告书》的规定，本报告书已全面披露信 ...